All In Biotech

Drug Trial Radar · NCT05298423

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

610

Actual

Start

May 3, 2022

Primary completion

Jun 15, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • pembrolizumab/vibostolimabBiological

    Administered as an intravenous (IV) infusion

  • durvalumabBiological

    Administered as an IV infusion

  • cisplatinDrug

    Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3

  • pemetrexedDrug

    Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only

  • etoposideDrug

    Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;

  • carboplatinDrug

    Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion

  • paclitaxelDrug

    Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion

  • thoracic radiotherapyRadiation

    60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 48 months
  2. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 48 months

Locations

160 sites in 25 countries. Site status is shown where the registry gives one.

  • VA Long Beach Healthcare System ( Site 2831)

    Long Beach, California

  • VA West Los Angeles Medical Center ( Site 2808)

    Los Angeles, California

  • Millennium Oncology Research Clinic ( Site 2801)

    Hollywood, Florida

  • Mid Florida Hematology and Oncology Center ( Site 2800)

    Orange City, Florida

  • Moffitt Cancer Center ( Site 2818)

    Tampa, Florida

  • University of Chicago Medical Center ( Site 2828)

    Chicago, Illinois

  • Franciscan St. Francis Health ( Site 2812)

    Indianapolis, Indiana

  • MFSMC-HJWCI ( Site 2804)

    Baltimore, Maryland

  • Boston Medical Center ( Site 2829)

    Boston, Massachusetts

  • University of Massachusetts Chan Medical School ( Site 2815)

    Worcester, Massachusetts

  • University of Missouri Hospital ( Site 2839)

    Columbia, Missouri

  • Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)

    Springfield, Missouri

  • Rutgers Cancer Institute of New Jersey ( Site 2805)

    New Brunswick, New Jersey

  • Icahn School of Medicine at Mount Sinai ( Site 2821)

    New York, New York

  • White Plains Hospital ( Site 2835)

    White Plains, New York

  • Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816)

    Portland, Oregon

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827)

    Lancaster, Pennsylvania

  • Thomas Jefferson University - Clinical Research Institute ( Site 2813)

    Philadelphia, Pennsylvania

  • Millennium Research & Clinical Development ( Site 2811)

    Houston, Texas

  • Central Texas Veterans health care-Oncology & Hematology ( Site 2819)

    Temple, Texas

  • MultiCare Health System ( Site 2817)

    Tacoma, Washington

  • Clinica Adventista Belgrano ( Site 3601)

    Caba., Buenos Aires F.D., Argentina

  • Instituto Médico Río Cuarto ( Site 3600)

    Río Cuarto, Córdoba Province, Argentina

  • Sanatorio Parque ( Site 3602)

    Rosario, Santa Fe Province, Argentina

  • Canberra Hospital ( Site 0010)

    Canberra, Australian Capital Territory, Australia

  • Icon Cancer Centre Hobart ( Site 0003)

    Hobart, Tasmania, Australia

  • Ballarat Health Services-Medical Oncology ( Site 0002)

    Ballarat Central, Victoria, Australia

  • Frankston Hospital-Oncology and Haematology ( Site 0009)

    Frankston, Victoria, Australia

  • St Vincent's Hospital-Oncology Clinical Trials ( Site 0005)

    Melbourne, Victoria, Australia

  • Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105)

    Rio de Janeiro, Brazil

  • A. C. Camargo Cancer Center-CAPEC ( Site 0102)

    São Paulo, Brazil

  • Hospital Nossa Senhora da Conceição ( Site 0111)

    Porto Alegre, Rio Grande do Sul, Brazil

  • James Lind Centro de Investigacion del Cancer ( Site 0202)

    Temuco, Araucania, Chile

  • Biocenter ( Site 0208)

    Concepción, Biobio, Chile

  • FALP-UIDO ( Site 0205)

    Santiago, Region M. de Santiago, Chile

  • Centro de Oncología de Precisión ( Site 0209)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0200)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 0203)

    Viña del Mar, Valparaiso, Chile

  • Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328)

    Beijing, Beijing Municipality, China

  • Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)

    Beijing, Beijing Municipality, China

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.